Details
Category: Volume 07 Issue 05 May 2019
Hits: 1748

Title: A  Study on the efficacy and safety of Myoinositol and Metformin in the treatment of PCOS

Authors: Dr Mamta Rani, Prof. Dr Mamta Singh, DGO, M.D.

 DOI: https://dx.doi.org/10.18535/jmscr/v7i5.115

Abstract

Objective

Clinical and metabolic data to compare the efficacy of myoinositol and metformin in subjects with polycystic ovarian syndrome (PCOS) are limited.  Present study was performed to compare myoinositol and metformin in subjects with PCOS.

Introduction

Polycystic ovarian syndrome (PCOS) is a complex condition with multisystem endocrinopathy posing a challenge to female fertility. It is the most common cause of menstrual disturbance, ovarian dysfunction, infertility and metabolic disorders including hyperandrogenism, glucose intolerance and insulin resistance in females of reproductive age. It has significant and diverse clinical implications including reproductive (infertility, hyperandrogenism, hirsutism), metabolic (insulin resistance, impaired glucose tolerance, type 2 diabetes mellitus, adverse cardiovascular risk profiles) and psychological features (increased anxiety, depression and worsened quality of life).1

As many as 20% of women with infertility problems (including fecundability and early pregnancy loss) have been diagnosed with PCOS.2 It is often called the most common cause of anovulatory infertility in women.3 The incidence has increased in recent years due to change in lifestyle and stress.2

References

  1. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010 Jun 30;8:41. doi: 10.1186/1741-7015-8-41. PubMed PMID: 20591140; PubMed Central PMCID: PMC2909929.
  2. Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol. 1998;138: 269–274
  3. Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsituism. Br Med J (Clin Res Ed) 1986;293:355–359.
  4. Legro RS, Strauss JF. Molecular progress in infertility: polycystic ovary syndrome. FertilSteril. 2002;78:569–576. doi: 10.1016/S0015-0282(02)03275-2. 
  5. Doi SA, Al-Zaid M, Towers PA, Scott CJ, Al-Shoumer KA. Ovarian steroids modulate neuroendocrine dysfunction in polycystic ovary syndrome. J Endocrinol Invest. 2005;28:882–892.
  6. Croze M L, Soulage C O “ Potential role and therapeutic interests of Myoinositol in metabolic diseases.
  7. Mansour A, Hosseini S, Larijani B, et al. Nutrients as novel therapeutic approaches for metabolic disturbances inpolycystic ovary syndrome. EXCLI J. 2016;15:551–564.
  8. Ozegowska K, Bogacz A, Bartkowiak-Wieczorek J, et al. Association between the angiotensin converting enzymegene insertion/deletion polymorphism and metabolic disturbances in women with polycystic ovary syndrome. MolMed Rep.2016;14:5401–5407.
  9. Costantino D, Minozzi G, Minozzi E, et al. Metabolic and hormonal effects of myo-inositol in women with polycysticovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci. 2009;13:105–110.
  10. Genazzani AD, Lanzoni C, Ricchieri F, et al. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol. 2008;24:139–144.
  11. Fruzzetti F, Perini D, Russo M, et al. Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). Gynecol Endocrinol. 2017;33:39–42.
  12. Mehri Jamilian; Pegah Farhat; Fatemeh Foroozanfard; Faraneh Afshar Ebrahimi; Esmat Aghadavod; Fereshteh Bahmani; Bita Badehnoosh; Hamidreza Jamilian; Zatollah Asemi Clin Endocrinol. 2017;87(2):194-200.
  13. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. (2003) Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction, 19, 41-47.
  14. Dona G, Sabbadin C, Fiore C, et al. Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome. Eur J Endocrinol. 2012;166:703–710.
  15. Gerli S, Papaleo E, Ferrari A, et al. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007;11:347–354.
  16. Raffone E, Rizzo P, Benedetto V. Insulin sensitizer alone and in co treatmeny with r-FSH for ovulation induction in PCOS women: Gynaecol. Endocrinol. 2010, 26:275-280.
  17. Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in PCOS with insulin resistance. Gynaecol. Endocrinol. 2015, 31(2): 13-15.

Corresponding Author

Prof. Dr Mamta Singh, DGO, M.D.

Department of Obstetrics & Gynaecology, Nalanda Medical College, Patna